251 related articles for article (PubMed ID: 12942110)
81. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
82. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
[TBL] [Abstract][Full Text] [Related]
83. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
[TBL] [Abstract][Full Text] [Related]
84. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Liu HY; Ding L; Yu Y; Chu Y; Zhu H
Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
[TBL] [Abstract][Full Text] [Related]
85. Oral therapy for colorectal cancer: how to choose.
Damjanov N; Meropol NJ
Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
[TBL] [Abstract][Full Text] [Related]
86. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
[TBL] [Abstract][Full Text] [Related]
87. The oral fluorinated pyrimidines.
de Bono JS; Twelves CJ
Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
[TBL] [Abstract][Full Text] [Related]
88. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
89. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
90. Pharmacology of fluorinated pyrimidines: eniluracil.
Baker SD
Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
[TBL] [Abstract][Full Text] [Related]
91. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
92. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
93. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
[TBL] [Abstract][Full Text] [Related]
94. Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics.
Watanabe M; Tateishi T; Takezawa N; Tanaka M; Kumai T; Nakaya S; Kobayashi S
Cancer Chemother Pharmacol; 2001 Mar; 47(3):250-4. PubMed ID: 11320669
[TBL] [Abstract][Full Text] [Related]
95. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
96. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Peer CJ; McManus TJ; Hurwitz HI; Petros WP
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
[TBL] [Abstract][Full Text] [Related]
97. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.
Davis ST; Joyner SS; Baccanari DP; Spector T
Biochem Pharmacol; 1994 Jul; 48(2):233-6. PubMed ID: 8053919
[TBL] [Abstract][Full Text] [Related]
98. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
[TBL] [Abstract][Full Text] [Related]
99. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
[TBL] [Abstract][Full Text] [Related]
100. S-1 as a core anticancer fluoropyrimidine agent.
Miura K; Shirasaka T; Yamaue H; Sasaki I
Expert Opin Drug Deliv; 2012 Mar; 9(3):273-86. PubMed ID: 22235991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
